ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants
Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who...
Gespeichert in:
Veröffentlicht in: | Cell reports (Cambridge) 2022-05, Vol.39 (5), p.110757-110757, Article 110757 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1–2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response.
[Display omitted]
•AZD1222 vaccination elicits monoclonal antibodies with potent neutralization•Vaccine antibodies target epitopes overlapping infection-induced antibodies•Vaccine antibodies have broad neutralization activity against VOCs, including Omicron•Despite low serum neutralization, Spike-reactive B cells are detected at 9 months
Seow et al. isolate antibodies following double vaccination with AZD1222. Isolated antibodies target epitopes overlapping with the epitopes of infection-derived antibodies and show potent neutralization of SARS-CoV-2 variants of concern (VOCs), including Omicron. Despite low serum neutralization at 9 months post-vaccine, Spike-reactive B cells are detected. |
---|---|
ISSN: | 2211-1247 2211-1247 |
DOI: | 10.1016/j.celrep.2022.110757 |